Botulinum toxin type B: A new injectable treatment for cervical dystonia

A. Brashear

doi:10.1517/13543784.10.12.2191

Botulinum toxin type B: A new injectable treatment for cervical dystonia

A. Brashear

Research output: Contribution to journal › Article

12 Scopus citations

Abstract

Cervical dystonia (CD) causes involuntary muscle spasms and is often associated with pain. Recently, botulinum toxin type B (BTX-B) (Myobloc™, Elan South San Francisco, CA, USA) was approved for general use in the treatment of CD in the USA. In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD.

Original language	English (US)
Pages (from-to)	2191-2199
Number of pages	9
Journal	Expert Opinion on Investigational Drugs
Volume	10
Issue number	12
DOIs	https://doi.org/10.1517/13543784.10.12.2191
State	Published - Dec 31 2001
Externally published	Yes

Keywords

Botulinum toxin
Cervical dystonia
Chemodenervation
Myobloc™
NeuroBloc®

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1517/13543784.10.12.2191

Fingerprint Dive into the research topics of 'Botulinum toxin type B: A new injectable treatment for cervical dystonia'. Together they form a unique fingerprint.

Cite this

Brashear, A. (2001). Botulinum toxin type B: A new injectable treatment for cervical dystonia. Expert Opinion on Investigational Drugs, 10(12), 2191-2199. https://doi.org/10.1517/13543784.10.12.2191

@article{4c0346b52a744fe48a3edc48b0d2e0fe,

title = "Botulinum toxin type B: A new injectable treatment for cervical dystonia",

abstract = "Cervical dystonia (CD) causes involuntary muscle spasms and is often associated with pain. Recently, botulinum toxin type B (BTX-B) (Myobloc{\texttrademark}, Elan South San Francisco, CA, USA) was approved for general use in the treatment of CD in the USA. In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD.",

keywords = "Botulinum toxin, Cervical dystonia, Chemodenervation, Myobloc{\texttrademark}, NeuroBloc{\textregistered}",

author = "A. Brashear",

year = "2001",

month = dec,

day = "31",

doi = "10.1517/13543784.10.12.2191",

language = "English (US)",

volume = "10",

pages = "2191--2199",

journal = "Expert Opinion on Investigational Drugs",

issn = "1354-3784",

number = "12",

}

TY - JOUR

T1 - Botulinum toxin type B

T2 - A new injectable treatment for cervical dystonia

AU - Brashear, A.

PY - 2001/12/31

Y1 - 2001/12/31

N2 - Cervical dystonia (CD) causes involuntary muscle spasms and is often associated with pain. Recently, botulinum toxin type B (BTX-B) (Myobloc™, Elan South San Francisco, CA, USA) was approved for general use in the treatment of CD in the USA. In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD.

AB - Cervical dystonia (CD) causes involuntary muscle spasms and is often associated with pain. Recently, botulinum toxin type B (BTX-B) (Myobloc™, Elan South San Francisco, CA, USA) was approved for general use in the treatment of CD in the USA. In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD.

KW - Botulinum toxin

KW - Cervical dystonia

KW - Chemodenervation

KW - Myobloc™

KW - NeuroBloc®

UR - http://www.scopus.com/inward/record.url?scp=0035215847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035215847&partnerID=8YFLogxK

U2 - 10.1517/13543784.10.12.2191

DO - 10.1517/13543784.10.12.2191

M3 - Article

C2 - 11772315

AN - SCOPUS:0035215847

VL - 10

SP - 2191

EP - 2199

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 12

ER -